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ticipated in this study. Of the respondents 55% were females, 69% worked in a 
chain pharmacy, with an average 11 years of work experience. 65% of the respon-
dents were aware of the labeling changes introduced by the FDA. Attitude of phar-
macists towards all the speciﬁc labeling changes introduced for acetaminophen and 
NSAIDs were positive. Pharmacists strongly and signiﬁcantly agreed (p < 0.001) 
that labeling changes like highlighting ingredient name or mentioning it in bold print 
(3.84 ± 1.08), appearance of “See New Warnings” statement on the principal display 
panel for one year (3.96 ± 1.06), age speciﬁc warnings for adults and for children 
below 12 years of age (4.12 ± 1.19), mentioning the maximum daily dosage units 
of acetaminophen under liver warnings (4.31 ± 1.06), will be useful for patients. 
CONCLUSIONS: The results indicate that majority of pharmacists agreed with 
FDA’s labeling changes for OTC IAAA drug products. More information regarding 
these changes should be provided to pharmacists and consumers to increase appro-
priate use of these products.
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OBJECTIVES: Experience indicated that the quality of economic evaluations submit-
ted in reimbursement dossiers and critical appraisals are heterogeneous. The objective 
of this study was to analyse the quality of submitted economic studies and related 
critical appraisal processes and to develop a policy-relevant, publicly available Slovak 
critical appraisal checklist for improving the quality of economic evaluation and 
budget impact analyses for reimbursement submission of dossiers concerning to drugs 
and medical devices. METHODS: We created a working group to review previously 
submitted economic evaluations and related critical appraisals in order to identify 
potential technical and methodological problems. The working group consisted of 
independent academic experts who scrutinized previous submissions and critical 
appraisals and developed a new checklist. Overall 50 economic evaluations submitted 
for reimbursement of drugs and medical devices in 2007–2009 were scrutinized. 
RESULTS: Evidence suggests that Slovak pharmaceutical expenditures do not result 
in the most cost-effective outcomes. Several potentially not cost-effective pharmaceu-
ticals have been reimbursed in Slovakia. Economic evaluations of drugs and medical 
devices are mandatory but the quality of evaluations and critical appraisals are rather 
poor. Therefore in addition to the available Slovak health economic evaluation guide-
lines a detailed checklist for appraisal processes have to be prepared. Our analysis 
shows that the simpliﬁed questionnaire, which is currently used for the critical 
appraisal process within Slovakia should be replaced by a new Slovak critical appraisal 
checklist, which will be detailed enough to address the most common problems in the 
local economic evaluations and budget impact analyses for decision making process. 
CONCLUSIONS: The transparent method of technology assessment can improve the 
consistency of reimbursement decisions making related to drugs and medical devices 
in Slovakia. The current checklist for critical appraisal is not sufﬁcient enough and 
there is signiﬁcant room for improvement in this ﬁeld.
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OBJECTIVES: The objective of this study was to evaluate outcomes of a bedside 
barcode technology intervention on medication administration time in an intensive 
care unit (ICU). METHODS: A prospective observational time-and-motion experi-
mental study was conducted by considering two medication administration processes 
(a paper based approach vs. the bedside barcode system) in a large 500+ bed hospital 
setting. Medication administration by the nurse was operationalized as activities such 
as direct or indirect patient care, administration, and miscellaneous. Time devoted to 
complete these medication administration activities were measured separately by 
means of two pre-calibrated stop watches. Complexity factors of medication admin-
istration (age, sex, body-weight, comorbidities, number of drugs administered, and 
length of ICU stay) were included in linear regression model to predict time required 
for each of those medication administration activities. RESULTS: One hundred and 
ﬁfty-one electronically documented medication administrations with the bedside 
barcode system were evaluated Mean times of direct patient care activity (182.32 ± 
131.68 seconds) and administration activity (59.83 ± 74.53 seconds) during bedside 
barcode medication administration improved signiﬁcantly in comparison with paper 
based approach. In the bedside barcode system, signiﬁcant (p < 0.05) predictors of 
time associated with direct patient care activity was number of drugs administered, 
for indirect patient care activity was comorbidities, and for administration activity 
was length of ICU stay. CONCLUSIONS: Variables that predict medication admin-
istration time in the bedside barcode system were different across the categorized 
activities. To develop and implement efﬁcient systems, such variables should be moni-
tored and controlled as high cost technology is adopted by hospitals.
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OBJECTIVES: A goal of evidence review is to inform policy decisions such as for 
insurance. This study examines whether and how U.S. payers use evidence reviews in 
policy decisions for personalized medicine. METHODS: We used literature review, 
focused interviews and a Roundtable meeting. Literature review was used to review 
and compare seven evaluation frameworks available to guide payer decisions: Blue 
Cross Blue Shield Technology Evaluation Center (BCBS TEC); ECRI Institute, Evalu-
ation of Genomic Applications in Practice and Prevention, Institute for Clinical and 
Economic Review, Hayes, Inc., Up-To-Date and United States Preventive Services Task 
Force. Seventeen interviews of health plan executives were used to identify whether 
and how these frameworks were used in policy decisions made by individual plans. A 
meeting that included interviewees and other thought leaders was used to discuss 
similarities and differences across payers in whether and how formal evaluations 
informed policy. The study focused on personalized medicine, the use of genetics or 
genomics to guide health care decisions. RESULTS: We found that frameworks vary 
in: purpose, questions of interest, range of evidence included, availability, and capac-
ity. All frameworks were used by at least one payer to inform policy decisions with 
one framework (BCBS TEC) used by all but one interviewed payer. All payers reported 
using multiple frameworks. Payers reported key gaps in frameworks including: lack 
of evidence on health care system factors, lack of timeliness and lack of breadth. 
Across payers the range of evidence used to inform decisions was believed to result in 
policy variation. In particular, when clinical evidence is uncertain but decisions 
needed, payers reported using nonclincal evidence to help guide decisions. CONCLU-
SIONS: Payers use evidence reviews to inform policy decisions but no single frame-
work is sufﬁcient. Key ways to improve reviews for insurance policy decisions might 
focus on balancing the tension between comprehensiveness and timeliness.
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OBJECTIVES: Health technology assessment (HTA) is used to evaluate health care 
technologies (e.g., pharmaceuticals, medical devices, and diagnostics) with respect to 
cost and their projected impact on patient outcomes and society. Currently, there is 
an ongoing initiative by the International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) to develop Road Maps that describe the utilization of HTA 
in health care. The purpose of this study was to develop models for HTA decision-
making structures along with reimbursement road maps for several countries. 
METHODS: Members of the ISPOR Special Interest Group (SIG) for HTA contacted 
key individuals in several countries, including: Austria, Demark, Hungary, Ireland, 
France, Germany, Denmark, UK, Sweden, Australia, Canada, Taiwan, United States, 
and others. Once decision models and corresponding reimbursement road maps were 
developed within designated HTA subgroups, the information was disseminated to all 
HTA committee members for review. After review, the decision models were sent to 
key stakeholders in each selected country for review and validation. RESULTS: Deci-
sion-making structures and review processes for reimbursement were developed for 
the selected counties. Key decision makers and/or third-party payers (e.g., person or 
organization) were identiﬁed and deﬁned in accordance with their role in the reim-
bursement process. Evaluators were deﬁned as individuals or organizations that 
provide input into the decision-making process regarding HTA development, but may 
not be responsible for ﬁnal coverage and payment decisions. CONCLUSIONS: Deci-
sion structures for reimbursement (e.g., coverage, coding, and payment) vary accord-
ing to the type of product (e.g., pharmaceutical, medical device, and diagnostic), the 
individual country and in some instances, by regions within the country. The HTA-SIG 
will continue to identify and validate HTA decision pathways for reimbursement 
within each country to provide guidance to manufacturers and policy makers in a way 
that optimizes efﬁciencies and supports the ongoing societal needs for access to emerg-
ing technologies.
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OBJECTIVES: The assessment of medical technologies in hospitals is often an unstruc-
tured not transparent process, only involving a small group of decision makers. To 
overcome barriers while discussing or implementing decisions, a clear communication 
A98 Abstracts
of how technologies are chosen is essential. The decision criteria and its weights should 
represent the management’s as well as the potential user’s perspective of the technol-
ogy. METHODS: To identify relevant criteria in terms of technology acquisition, a 
literature review was carried out. As a second step 221 HTA-experts were confronted 
with the ten most frequent criteria, with the task to evaluate their importance and to 
supplement them. To evaluate the individual weight of each criterion a survey was 
conducted, including three relevant user groups within the sector of radiooncology. 
For each of the 115 recipients and an overall preference proﬁle was calculated using 
an AHP-model. The inﬂuence of factors such as job, leadership, sex, user, size of 
hospital and typ of hospital were also analyzed using an analysis of variance. 
RESULTS: As result of step one and two the following seven criteria were identiﬁed: 
effectiveness, the need for treatment, patient preferences, usability, cost-effectiveness, 
organizational impact, budget impact. The overall AHP-model identiﬁed the organi-
zational impact (16.9%) as the most relevant criterion, followed by the budget impact 
(15.7%). The variance analysis showed that all factors, except the size of the hospital 
inﬂuence certain criteria of the preference proﬁle in a signiﬁcant way. CONCLU-
SIONS: Surprisingly, the organizational impact is the most important criterion directly 
followed by the budget impact. The organizational impact is today often underesti-
mated. Therefore, organizational barriers exist and can delay or hinder innovation. 
To determine essential characteristics of a new technology and to lower barriers 
regarding its acceptance, the preferences of each group should be evaluated and 
integrated in decisions.
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OBJECTIVES: The purpose of this study is to better understand the types of evidence 
considered and how evidence is used by health care payers and payer intermediary 
organizations to evaluate prescription drugs and biologics for possible formulary 
inclusion. METHODS: We conducted semi-structured one-hour telephone interviews 
with key decision makers at payers and payer intermediary organizations. Respon-
dents included medical and pharmacy directors who actively participate in pharma-
ceutical technology assessment (PTA). Participants were asked to describe their PTA 
process and to rate the importance of the sources and types of evidence they review. 
RESULTS: Pharmacy and medical directors from 15 national and regional health 
plans, prescription drug plans, and pharmacy beneﬁt managers rated information used 
for PTA on a scale of 1 (not important) to 5 (very important). While preliminary 
results indicate that respondents rated peer-reviewed studies as the most important 
source of information (mean = 4.7), technology assessments such as comparative 
effectiveness studies (e.g., from AHRQ or Hayes) and internal (health plan) data on 
utilization were rated almost as highly (4.2 and 4.1, respectively). Medical directors 
gave comparative effectiveness studies higher ratings than did pharmacy directors (4.7 
vs. 3.8; p < 0.001). Among types of evidence, randomized control trials (RCTs) were 
rated the highest (mean = 4.6); budget impact analyses (mean = 3.1) and pharmaco-
economic studies (mean = 2.9) had substantially lower rating, although both of these 
received higher ratings from pharmacy vs. medical directors. There was little variation 
in ratings by payer type. CONCLUSIONS: While it is not surprising that key decision 
makers highly value RCTs from peer-review literature, other sources of information 
were rated as having essentially the same importance. Medical and pharmacy directors 
have signiﬁcant differences in the importance assigned to certain information. Addi-
tional data will help to explore variations in perceived value of information among 
different types of PTA staff and potentially differences across payer types.
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Farkowski MM1, Baran J1, Matusewicz W2
1Agency for Health Technology Assessment in Poland, Warsaw, Poland, 2Agency for Health 
Technology Assessment in Poland, Warsaw, Poland
OBJECTIVES: Consultative Council (CC) is an independent body playing a central 
role in decision making of Polish Heath Technology Assessment Agency (AHTAPol). 
We were interested in how much safety issues of the appraised technologies concern 
members of CC and what is the inﬂuence of safety issues on CC’s decisions. 
METHODS: We analyzed decisions of CC published until the end of 2009 and dis-
tinguish those where safety issues were signiﬁcant arguments for decline. We indentify 
the type of key documents quotabled in the decisions in order confront them with 
documents included in manufacturer’s HTA reports. RESULTS: Among 148 CC’s 
decisions analyzed, 70 were negative and in 22 safety issues were signiﬁcant arguments 
against the positive recommendation (31% of all negative decisions). Apart of the 
manufacturer’s HTA reports, CC based mainly on EMEA or national Summary Of 
Product Characteristics (91%), FDA reports and Cochrane reviews (23% each), RCT 
not included in the submission (17%) and non-systematic reviews (13%). Manufac-
turer’s HTA reports on safety included mainly III phase RCTs (77%), II phase RCTs 
(36%), observational studies (27%), systematic (non-Cochrane) or non-systematic 
reviews (9%). Seldom, if ever, submitted reports mentioned FDA or EMEA reports 
and patient registries (5%). CONCLUSIONS: Safety issues were important argument 
in negative opinions of CC. Unlike efﬁcacy, safety analysis comprise evidence other 
than III phase RCTs. Manufacturer’s HTA reports did not cover many documents 
signiﬁcant to CC regarding safety. A wider safety analysis according to the ATHAPol’s 
guidelines 2009 would be required.
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THERAPEUTIC CLASSES
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OBJECTIVES: Drugs receive priority (P) or standard (S) review based on FDA’s 
perceptions that the drug offers signiﬁcant beneﬁt over existing options. The study 
will describe patient characteristics associated with drugs that got P and S approval. 
METHODS: This pilot study employed a retrospective cohort design using MEPS data 
(full year consolidated, prescription medicine, and medical condition ﬁles) from 
2004–2007. Subjects were identiﬁed from the prescription medicine ﬁles if they 
received P drugs (atorvastatin, pioglitazone, rosiglitazone, repaglinide) or S drugs 
(simvastatin, pravastatin, rosuvastatin, glimepiride, exenatide, sitagliptin). All other 
drugs that were received by these subjects and approved 1990 onwards were coded 
for their approval status from the FDA website. Subjects in the S group receiving any 
P drug or who received the aforementioned drugs from both groups were excluded. 
Variables at the year subjects entered the MEPS were analyzed. RESULTS: A total of 
5835 patients—3810 patients on one or more P drugs and 2025 on S drugs—were 
identiﬁed. There was no signiﬁcant difference of age of the patients in these groups. 
Patients’ race and gender (Asian vs. White OR = 1.556; female vs. male OR = 1.367) 
was associated (p < 0.05) with odds of receiving priority drugs. Patients receiving P 
drugs had signiﬁcantly (p < 0.05) higher number of comorbidities compared to those 
in the S group. Respiratory diseases, endocrine disorders, tumor, hypertension, and 
number of comorbidities were signiﬁcant (p < 0.05) predictors of receiving P drugs. 
Patients in the P group reported signiﬁcantly (p < 0.05) poorer health status. However, 
when adjusted with propensity score such difference was not associated with the drug 
categories. CONCLUSIONS: Patient demographics was associated with receiving 
antidiabetic and anticholesterol therapeutic classes of drugs that received priority 
review. After controlling for comorbidities, number of comorbidities was positively 
associated with likelihood of receiving P drugs. When adjusted for covariates, such 
categorization was not associated with self-reported health status.
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Universidad Nacional de Colombia, Bogota, Colombia
OBJECTIVES: To evaluate drugs prescribing indicators of outpatient medication in 
medium- and high-level complexity hospitals from Colombia METHODS: This was 
a cross-sectional study where medication prescription was evaluated in 331 second- 
and third-level complexity hospitals from 27 Colombian departments during 2006–
2007 RESULTS: 38863 prescriptions for 3663 patients were analyzed; 54.7% of them 
patients afﬁliated to contributory health care system. Average prescribed medication 
per person was 2,2 (2,1–2,2 95 % CI), the percentage of antibiotics formulated by 
prescription was 29,2 % (28,7–29,6 95 % CI), essential prescribed medicines 
accounted for 64,2 % (63,7–64,6 95 % CI) and injectable medicines was 22,1 % 
(21,7–25,5 %). More than half the medications (62,1 %; 61,5–62,7 95 % CI) were 
in three ATC groups (anti-infectious agents, immunomodulating agents and medica-
tions for the alimentary and metabolic tract). DU90% consisted of 64 medications 
and the medication consumption was of 8, 39 daily deﬁned doses (DDD)/1000 patients 
CONCLUSIONS: Respect to previous studies in Colombia the indicators remain with 
few change, except the percentage of antibiotics formulated by prescription that 
increased more than recommended by OMS (25%). This is the ﬁrst report of DU90% 
and DDD in Colombian patients and these indicators must be continuously evaluated 
in future to follow the quality of prescription and drug consumption.
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OBJECTIVES: To evaluate the knowledge change among medical, pharmacy, and 
nurse practitioner students after attending a drug-drug interaction (DDI) educational 
program. METHODS: Students were given a DDI knowledge assessment containing 
15 drug pairs. They were asked to assess each drug pair and select the corresponding 
appropriate management strategy. Following the knowledge assessment, students 
attended a 45-minute training program during which all 15 drug pairs were addressed. 
The ﬁrst outcome of interest was “Management Strategy,” where students were given 
credit only if they selected the correct management strategy. Actions included “Avoid 
